All In Biotech

Drug Trial Radar · NCT07087327

A Long-term Trial of EB-1020 in Pediatric Patients With ADHD

A Phase 3, Multicenter, Open-label, Uncontrolled, Long-term Japan-China Joint Trial to Evaluate the Safety and Efficacy of EB-1020 QD XR Capsules Administered Orally Once Daily in Children and Adolescents With Attention- Deficit/Hyperactivity Disorder

Last checked: Nov 19, 2026Latest source record: Dec 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Sep 16, 2025

Primary completion

Aug 2027

Study completion Aug 2027

Sponsor

Sponsor type
Industry
First posted
Jul 28, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 6 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety of long-term administration of mainly high doses of EB-1020 over 52 weeks in pediatric ADHD patients.

Conditions

  • Attention-Deficit Hyperactivity Disorder(ADHD)

Interventions

  • EB-1020 (Centanafadine) low doseDrug

    low dose, capsule, oral, once daily, for 52 weeks

  • EB-1020 (Centanafadine) high doseDrug

    high dose, capsule, oral, once daily, for 52 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Patients Experiencing Treatment-Emergent Adverse Events (TEAEs)Time frame: Baseline, week52

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hokkaido University Hospital

    Sapporo, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.